1
Gene Hung, Janet M Leeds, C Frank Bennett, Susan M Freier: Compositions and their uses directed to huntingtin. Isis Pharmaceuticals, CHDI Foundation, Casimir Jones S C, June 16, 2015: US09057066 (4 worldwide citation)

Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are metho ...


2
John Wityak, Leticia M Toledo Sherman, Celia Dominguez, Stephen Martin Courtney, Christopher John Yarnold, Paula C De Aguiar Pena, Andreas Scheel, Dirk Winkler: Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. CHDI Foundation, September 17, 2013: US08536186 (3 worldwide citation)

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO act ...


3
John Wityak, Leticia M Toledo Sherman, Celia Dominguez, Stephen Martin Courtney, Christopher John Yarnold, Paula C De Aguiar Pena, Andreas Scheel, Dirk Winkler: Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. CHDI FOUNDATION, September 29, 2015: US09145373 (1 worldwide citation)

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO act ...


4
Celia Dominguez, Leticia M Toledo Sherman, Stephen Martin Courtney, Michael Prime, William Mitchell, Christopher John Brown, Paula C De Aguiar Pena, Peter Johnson: Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. CHDI Foundation, February 16, 2016: US09260422 (1 worldwide citation)

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO act ...


5

6
Stephen Martin Courtney, Michael Prime, William Mitchell, Christopher John Brown, Paula C De Aguiar Pena, Peter Johnson, Celia Dominguez, Leticia M Toledo Sherman, Ignacio Muñoz Sanjuan: Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. CHDI Foundation, Sheppard Mullin Richter & Hampton, August 30, 2016: US09428464

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO act ...


7
Leticia M Toledo Sherman, Celia Dominguez, Michael Prime, William Leonard Mitchell, Peter Johnson, Naomi Went: Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. CHDI Foundation, Sheppard Mullin Richter & Hampton, November 21, 2017: US09822058

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehic ...


8
Celia Dominguez, Leticia Toledo Sherman, Michael Prime, William Mitchell, Naomi Went: Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. CHDI Foundation, Sheppard Mullin Richter & Hampton, April 10, 2018: US09938252

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehic ...


9

10